In Silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

Cancer Cell

Volumn 18, Issue 3, 2010, Pages 244-257

  Mir, Shahryar E ^a   De Witt Hamer, Philip C ^a   Krawczyk, Przemek M ^b   Balaj, Leonora ^a   Claes, An ^c   Niers, Johanna M ^a,d   Van Tilborg, Angela A G ^b   Zwinderman, Aeilko H ^b   Geerts, Dirk ^b   Kaspers, Gertjan J L ^a   Peter Vandertop, W ^a   Cloos, Jacqueline ^a   Tannous, Bakhos A ^d   Wesseling, Pieter ^c   Aten, Jacob A ^b   Noske, David P ^a   Van Noorden, Cornelis J F ^b   Würdinger, Thomas ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1 ENZYME; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PD 0166285; PROTEIN P53; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; COMPUTER MODEL; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MICROARRAY ANALYSIS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

PYRONIA TITHONUS;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; G2 PHASE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MICROARRAY ANALYSIS; MITOSIS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956517283     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.08.011     Document Type: Article

References (68)

1. Agulnik M., da Cunha Santos G., Hedley D., Nicklee T., Dos Reis P.P., Ho J., Pond G.R., Chen H., Chen S., Shyr Y., et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J. Clin. Oncol. 2007, 25:2184-2190.
2. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
3. Branzei D., Foiani M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 2008, 9:297-308.
4. Bredel M., Bredel C., Juric D., Harsh G.R., Vogel H., Recht L.D., Sikic B.I. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005, 65:8679-8689.
5. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
6. Candolfi M., Curtin J.F., Nichols W.S., Muhammad A.G., King G.D., Pluhar G.E., McNiel E.A., Ohlfest J.R., Freese A.B., Moore P.F., et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol. 2007, 85:133-148.
7. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
8. Claes A., Schuuring J., Boots-Sprenger S., Hendriks-Cornelissen S., Dekkers M., van der Kogel A.J., Leenders W.P., Wesseling P., Jeuken J.W. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol. 2008, 18:423-433.
9. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 2002, 1:309-315.
10. de Jager M., Dronkert M.L., Modesti M., Beerens C.E., Kanaar R., van Gent D.C. DNA-binding and strand-annealing activities of human Mre11: implications for its roles in DNA double-strand break repair pathways. Nucleic Acids Res. 2001, 29:1317-1325.
11. De Witt Hamer P.C. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-oncol. 2010, 12:304-316.
12. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347:472-480.
13. Elder R.T., Yu M., Chen M., Zhu X., Yanagida M., Zhao Y. HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology 2001, 287:359-370.
14. Featherstone C., Russell P. Fission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase. Nature 1991, 349:808-811.
15. Goldberg M., Stucki M., Falck J., D'Amours D., Rahman D., Pappin D., Bartek J., Jackson S.P. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 2003, 421:952-956.
16. Hashimoto O., Shinkawa M., Torimura T., Nakamura T., Selvendiran K., Sakamoto M., Koga H., Ueno T., Sata M. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyrimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006, 6:292.
17. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001, 61:1957-1963.
18. Hodgson J.G., Yeh R.F., Ray A., Wang N.J., Smirnov I., Yu M., Hariono S., Silber J., Feiler H.S., Gray J.W., et al. Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts. Neuro. Oncol. 2009, 11:477-487.
19. Iliakis G., Wang Y., Guan J., Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003, 22:5834-5847.
20. Katayama K., Fujita N., Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol. Cell. Biol. 2005, 25:5725-5737.
21. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3:513-519.
22. Kim S.Y., Ferrell J.E.J. Substrate competition as a source of ultrasensitivity in the inactivation of Wee1. Cell 2007, 128:1133-1145.
23. Klein A., Reichardt W., Jung V., Zang K.D., Meese E., Urbschat S. Overexpression and amplification of STK15 in human gliomas. Int. J. Oncol. 2004, 25:1789-1794.
24. Kortmansky J., Shah M.A., Kaubisch A., Weyerbacher A., Yi S., Tong W., Sowers R., Gonen M., O'Reilly E., Kemeny N., et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. 2005, 23:1875-1884.
25. Kotliarov Y., Steed M.E., Christopher N., Walling J., Su Q., Center A., Heiss J., Rosenblum M., Mikkelsen T., Zenklusen J.C., et al. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res. 2006, 66:9428-9436.
26. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
27. Lavin M.F. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 2007, 26:7749-7758.
28. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
29. Lee Y., Scheck A.C., Cloughesy T.F., Lai A., Dong J., Farooqi H.K., Liau L.M., Horvath S., Mischel P.S., Nelson S.F. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med. Genomics 2008, 1:52.
30. Li J., Wang Y., Sun Y., Lawrence T.S. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat. Res. 2002, 157:322-330.
31. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
32. Loffler H., Lukas J., Bartek J., Kramer A. Structure meets function-centrosomes, genome maintenance and the DNA damage response. Exp. Cell Res. 2006, 312:2633-2640.
33. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
34. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
35. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Yamagata M., Kurokohchi K., Uchida N., Miyauchi Y., Yoshiji H., Watanabe S., et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003, 37:534-543.
36. McGowan C.H., Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993, 12:75-85.
37. Nakano I., Masterman-Smith M., Saigusa K., Paucar A.A., Horvath S., Shoemaker L., Watanabe M., Negro A., Bajpai R., Howes A., et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J. Neurosci. Res. 2008, 86:48-60.
38. Nicholas M.K., Lukas R.V., Jafri N.F., Faoro L., Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res. 2006, 12:7261-7270.
39. Nurse P. Genetic control of cell size at cell division in yeast. Nature 1975, 256:547-551.
40. O'Connell M.J., Raleigh J.M., Verkade H.M., Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J. 1997, 16:545-554.
41. Omuro A.M.P., Faivre S., Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 2007, 6:1909-1919.
42. Parker L.L., Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
43. Pedersini R., Vattemi E., Mazzoleni G., Graiff C. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol. 2007, 8:1039-1040.
44. Peri S., Navarro J.D., Amanchy R., Kristiansen T.Z., Jonnalagadda C.K., Surendranath V., Niranjan V., Muthusamy B., Gandhi T.K.B., Gronborg M., et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res. 2003, 13:2363-2371.
45. Ravaud A., Hawkins R., Gardner J.P., von der Maase H., Zantl N., Harper P., Rolland F., Audhuy B., Machiels J.P., Petavy F., et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J. Clin. Oncol. 2008, 26:2285-2291.
46. Reinhardt H.C., Aslanian A.S., Lees J.A., Yaffe M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007, 11:175-189.
47. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
48. Rich J.N., Bigner D.D. Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov. 2004, 3:430-446.
49. Rogakou E.P., Boon C., Redon C., Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 1999, 146:905-916.
50. Rothblum-Oviatt C.J., Ryan C.E., Piwnica-Worms H. 14-3-3 binding regulates catalytic activity of human Wee1 kinase. Cell Growth Differ. 2001, 12:581-589.
51. Rowley R., Hudson J., Young P.G. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 1992, 356:353-355.
52. Russell K.J., Wiens L.W., Demers G.W., Galloway D.A., Le T., Rice G.C., Bianco J.A., Singer J.W., Groudine M. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:1099-1106.
53. Russell P., Nurse P. Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 1987, 49:559-567.
54. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., Abraham R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999, 59:4375-4382.
55. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000, 14:289-300.
56. Sidi S., Sanda T., Kennedy R.D., Hagen A.T., Jette C.A., Hoffmans R., Pascual J., Imamura S., Kishi S., Amatruda J.F., et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008, 133:864-877.
57. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
58. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. The Cancer Genome Atlas Research Network.
59. van Vugt M.A.T.M., Bras A., Medema R.H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell 2004, 15:799-811.
60. Vieth M., Sutherland J.J., Robertson D.H., Campbell R.M. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 2005, 10:839-846.
61. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
62. Wang Y., Decker S.J., Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol. Ther. 2004, 3:305-313.
63. Wang Y., Li J., Booher R.N., Kraker A., Lawrence T., Leopold W.R., Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001, 61:8211-8217.
64. Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N., Hunter T., Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc. Natl. Acad. Sci. USA 2004, 101:4419-4424.
65. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
66. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359:492-507.
67. Yoshida T., Tanaka S., Mogi A., Shitara Y., Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann. Oncol. 2004, 15:252-256.
68. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.